CTLA-4 Limits Anti-CD20-Mediated Tumor Regression.

ABSTRACT:

Purpose

The inhibition of tumor growth by anti-CD20 antibody (Ab) treatment is mediated by Ab- and complement-dependent cytotoxicity in xenograft tumor models. In addition, anti-CD20 therapy for B-cell lymphoma can result in intrinsic and extrinsic tumor resistance to further Ab treatment. However, adaptive immune response-related resistance has not been well studied in anti-CD20-mediated tumor control, and adaptive immunity has long been underestimated. The purpose of this study was to explore whether T cells are involved in mediating the effects of anti-CD20 therapy and what factors contribute to adaptive immune response-related resistance.

Experimental design

Using a syngeneic mouse B-cell lymphoma model, we investigated the role of CD8⁺ T cells in anti-CD20-me

SUBMITTER: Ren Z 

PROVIDER: S-EPMC5191988 | biostudies-literature | 2017 Jan

REPOSITORIES: biostudies-literature